Clinical Trials

Find a Parkview Health Clinical Trial

74 results found

Current Studies

Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma

Primary Objectives To compare the complete response rate at 6 cycles after randomization as defined by centrally read PET/CT (integral biomarker) of 2 targeted therapeutic regimens (obinutuzumab + TGR-1202 or obinutuzumab + lenalidomide) with obinutuzumab + CHOP in patients with early relapsing or...

View Details

Current Studies

Cryotherapy Ablation Therapy for the Treatment of Esophageal Cancer: A Retrospective Review

Primary: to assess the efficacy of cryoablation therapy in the treatment of esophageal adenocarcinoma as adjuvant, neoadjuvant or palliative therapy. Secondary: to assess the safety of cryoablation therapy in the treatment of esophageal cancer

View Details

Current Studies

Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure - Thrombolysis in Myocardial Infarction 68 ( DAPA ACT HF-TIMI 68)

PRIMARY OBJECTIVE To assess the effect of in©\hospital initiation of dapagliflozin, as compared with placebo, on the clinical outcomes of cardiovascular death or worsening heart failure in patients with heart failure with reduced ejection fraction (LVEF ¡Ü40%) who have been stabilized...

View Details

Current Studies

Intermediate-Size Patient Population Expanded Access of NanoPac® for the Treatment of Pancreatic Cancer

The objective of this expanded access is to provide NanoPac to patients with pancreatic adenocarcinoma who received NanoPac under clinical trial NANOPAC-2016-05 and have completed their participation in the formal clinical trial.

View Details

Current Studies

DecisionDx-Melanoma Impact on Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes (DECIDE)

Primary Aim 1. Determine the association of GEP test result with SLNB surgical decisions in patients with SLNB-eligible T1-T2 melanoma Primary Aim 2: Track and evaluate 5-year clinical outcomes for patients in each GEP subclass, including those who did and did not undergo SLNB and those with T3-T4...

View Details

Current Studies

An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Belzutifan (MK-6482) and Lenvatinib (MK-7902), or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First

Primary Objectives - Objective: To compare the HIF triplet to the doublet with respect to PFS per RECIST 1.1 as assessed by BICR. - Hypothesis (H1): The HIF triplet is superior to the doublet with respect to PFS per RECIST 1.1 by BICR in advanced ccRCC patients with IMDC intermediate/poor risk. -...

View Details

Current Studies

A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer

Primary Outcome Measures: 1. Overal Survival [Time Frame: From date of study entry until the date of death from any cause (up to 5 years)] 2. Progression Free Survival (PFS) by RECIST 1.1 [Time Frame: From date of study entry until the death from any cause, or up to 5 years after last study...

View Details

Current Studies

A Phase 3 Open-Label Clinical Study to Evaluate the Safety and Tolerability of Rebiotix RBX2660 (microbiota suspension) in Subjects with Recurrent Clostridium difficile Infection (PUNCH)

Primary Objective: To evaluate the safety and tolerability of RBX2660 in subjects with recurrent CDI. Secondary Objectives: 1. To evaluate the efficacy of RBX2660 in preventing recurrent episodes of CDI through 8 weeks after treatment. 2. To evaluate the sustained clinical response rate of...

View Details

Current Studies

Integrated Cancer Repository for Cancer Research (iCaRe2)- Subproject: Pancreatic Cancer Collaborative Registry

OBJECTIVES: Develop Integrated Biomedical Computing Tools (IBCT) for the better understanding and treatment of pancreatic cancer by using the power of computer and informatics sciences. Continue development of the Pancreatic Cancer Collaborative Registry (PCCR) infrastructure to act as a...

View Details

Current Studies

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Primary Objectives: To centrally test resected NSCLC for genetic mutations to facilitate accrual to randomized adjuvant studies. To obtain clinically annotated tumor tissue and patient-matched non-malignant DNA from peripheral blood, as well as detailed epidemiologic and clinical follow-up data, to...

View Details

Current Studies

Colorectal Endoscopic Mucosal Resection: A Chart Review Study of Outcomes

This study will determine recurrence and complication rates for those that have undergone endoscopic mucosal resection of colorectal polyps at Parkview Regional Medical Center.

View Details

Current Studies

Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy

The purpose of this study is to assess correlations between expression of blood serum biomarkers and cognitive impairment (CI) in patients with colorectal cancer throughout and following chemotherapy treatment. Our primary goal is to establish a panel of biomarkers that predict CI that can be...

View Details

Current Studies

ORACLE Registry Dr. Biswas Biodesix Nodify XL2

Primary Outcome Measures : Statistically significant change in the proportion of benign lung nodules managed by BDX-XL2 experiencing invasive procedures. [ Time Frame: Up to 2 years ]

View Details

Current Studies

A Phase 3 Randomized Study of Cystectomy plus Perioperative Pembrolizumab versus Cystectomy Alone in Cisplatin-ineligible Participants with Muscleinvasive Bladder Cancer (KEYNOTE-905)

- Objective: To compare pathologic complete response (pCR) rates obtained in Arm A (preoperative pembrolizumab and RC+PLND) and Arm B (RC+PLND), based on central pathologic review, evaluated in participants whose tumors express PD-L1 CPS ≥10 and all participants, irrespective of CPS score. -...

View Details

Current Studies

Quality of life assessment in patients receiving cryotherapy in addition to chemotherapy for palliation of unresectable esophageal or gastroesophageal cancer

Primary Objective: To determine the effect of cryoablation combined with chemotherapy on the quality of life (QOL) of patients with non-resectable esophageal or gastroesophageal cancer. Secondary Objective: To determine the effect of cryotherapy on dysphagia scores To describe the safety profile...

View Details

Current Studies

Neuroform® Microdelivery Stent System

The Neuroform Microdelivery Stent System is intended for use with embolic coils for the treatment of wide neck, intracranial, saccular aneurysms arising from a parent vessel with a diameter of ≥ 2 mm and ≤ 4.5 mm that are not amenable to treatment with surgical clipping. Wide neck...

View Details

Current Studies

KCP-330-024: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 TRIAL OF MAINTENANCE WITH SELINEXOR/ PLACEBO AFTER COMBINATION CHEMOTHERAPY FOR PATIENTS WITH ADVANCED OR RECURRENT ENDOMETRIAL CANCER

Primary Outcome Measures : Progression Free Survival (PFS) [ Time Frame: Time from randomization until disease progression (PD) or death, whichever occurs first (approximately 12 months after the last participant enrolled) ] Compare progression free survival of the two treatment arms as assessed...

View Details

Current Studies

Prospective Development and Validation of a Gene Expression Assay to Predict the Risk of Recurrence Disease in Cutaneous Squamous Cell Carcinoma

Primary endpoint: To prospectively validate a gene expression and/or mutation profile to predict the risk of recurrence associated with primary cSCC tumors Secondary endpoints: To further develop a gene expression profile assay through use of gene expression data, including that from subgroups...

View Details

Current Studies

Development and Validation of a Gene Expression Assay to Predict the Risk of Recurrence Disease in Cutaneous Squamous Cell Carcinoma

Primary Endpoint: To identify a gene expression and/or mutational profile that can separate primary cSCC tumors that have a high risk of recurrence compared to primary cSCC tumors that have a low risk of recurrence using RT-PCR and RNA sequencing (RNASeq). Secondary Endpoint: To validate the...

View Details

Current Studies

A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination With BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients With Molecular Evidence of Disease

Primary Objective To compare the rate of molecular response 4.5 (MR4.5) after 12 months of combination therapy with ruxolitinib plus a TKI (dasatinib or nilotinib) versus a TKI alone, based on local PCR testing to measure BCR-ABL transcripts in chronic phase CML patients with molecular evidence of...

View Details

Current Studies

Confocal Laser Endomicroscopy as an Imaging Biomarker for the Diagnosis of Pancreatic Cystic Lesions (CLIMB)

Primary Outcome Measures: Accuracy of PCL diagnosis [Time Frame: 48 months] Diagnostic accuracy of confocal laser endomicroscopy and/or cyst fluid molecular markers and/or composite clinical and imaging features for the diagnosis of mucinous PCLs, PCLs with malignant potential, specific PCL types,...

View Details

Current Studies

CT vs. Endoscopic Ultrasonography in Tumor Discovery and Diagnosis: A Chart Review Study

To identify the incidence of and variables associate with those patients found to have pancreatic tumors upon Endoscopic Ultrasound that were unidentifiable on CT/MRI imaging.

View Details

Current Studies

Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab

Primary Objective Phase II: To compare progression free survival (PFS) for patients with limited stage small cell lung cancer (LS-SCLC) treated with chemoradiation +/- atezolizumab. Phase III: To compare overall survival (OS) for patients with LS-SCLC treated with chemoradiation +/-...

View Details

Current Studies

Phase IIa Trial Evaluating the Safety of Intratumoral Injection of NanoPac® in Subjects with Locally Advanced Pancreatic Adenocarcinoma

Primary: 1.Incidence of Treatment Emergent Adverse Events (safety and tolerability) [ Time Frame: Up to 3 (three) months after NanoPac® injection ] Treatment Emergent Adverse Events will include laboratory assessments, physical examination findings, and vital signs. Secondary: 1.Pharmacokinetics:...

View Details

Current Studies

A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer (KEYNOTE-A18 / ENGOT-cx11)

Primary: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) [Time Frame: Up to approximately 38 months] Overall Survival (OS) [Time Frame: Up to approximately 46 months] Secondary: Progression-Free Survival (PFS) Per Response Evaluation...

View Details

Current Studies

Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Etripamil Nasal Spray for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia. The NODE-301 Trial.

The primary objective of this study is to determine whether etripamil nasal spray (NS) 70 mg is superior to placebo at terminating episodes of PSVT in an outpatient setting. Primary Outcome Measures: 1. The time to conversion of an episode of PSVT to sinus rhythm (SR) after study drug...

View Details

Current Studies

A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma

Co-primary Objectives To determine the progression free survival (PFS) for paclitaxel with and without nivolumab in subjects with taxane naïve angiosarcoma. To determine the overall response rate (ORR) of nivolumab in combination with cabozantinib in patients with taxane pre-treated...

View Details

Current Studies

Incidence and Risk Factors for the Recurrence of Ampullary Polyps after Endoscopic Papillectomy: A Multicenter, Retrospective Study

Central Hypothesis: Histological and endoscopic features of the papilla impact recurrence. Recurrence is higher in patients with Familial adenomatous polyposis than with sporadic adenomas of the papilla. Specific Aim #1: Rate of recurrence of ampullary adenomas in patients with and without...

View Details

Current Studies

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age greater than/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Primary Objective: To compare the progression-free survival (PFS) in patients with newly diagnosed advanced stage classical Hodgkin lymphoma randomized to N-AVD (nivolumab, doxorubicin, vinblastine, dacarbazine) versus that obtained with BV-AVD (brentuximab vedotin, doxorubicin, vinblastine,...

View Details

Current Studies

A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPCA

Primary Objectives Phase II To assess the efficacy of concurrent definitive therapy followed by nivolumab compared with concurrent definitive therapy followed by observation in terms of progression-free survival (PFS). Phase III To assess the efficacy of concurrent definitive therapy followed by...

View Details

Current Studies

Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Adjuvant Chemotherapy in High-Risk Patients With Early-Stage Cervical Carcinoma Following Radical Hysterectomy

Primary: To determine if adjuvant systemic chemotherapy following chemoradiation therapy will improve disease-free survival compared to chemoradiation therapy alone in patients with high-risk early-stage cervical carcinoma found to have positive nodes and/or positive parametria after a radical...

View Details

Current Studies

Endoscopic Mucosal Resection for Management (EMR) of Early Stage Esophageal Adenocarcinoma (EA)

The purpose of our retrospective and prospective study is to gather data about a group of patients that were treated with EMR for early stage EA to asses for overall survival, disease-free survival, complications of the procedure, quality of life after the interventions as well as compare patient...

View Details

Current Studies

MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry

Primary: Create a large scale, population-based registry of full genome expression data matched with clinical data to investigate new gene associations with prognostic and/or predictive value Utilize registry data to graduate identified expression signatures into subset trials and recommend...

View Details

Current Studies

Endoscopic Stenting in Esophageal Cancer: A Chart Review Study

It is the aim of this study to analyze the outcomes of endoscopic esophageal stent placement in those with esophageal cancer

View Details

Current Studies

PulseRider® Aneurysm Neck Reconstruction Device (ANRD)

PulseRider® is indicated for use with neurovascular embolic coils in patients greater than or equal to 18 years of age for the treatment of unruptured wide-necked intracranial aneurysms with neck widths greater than 4 mm or dome to neck ratio < 2 originating on or near a vessel bifurcation of the...

View Details

Current Studies

Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia (NODE-303)

Primary: 1. The primary objective is to evaluate the safety of self-administered etripamil nasal spray (NS) outside of the clinical setting. Secondary Objectives: 1. To evaluate the efficacy of self-administered etripamil NS outside of the clinical setting, and 2. To evaluate the impact of...

View Details

Current Studies

A Phase 3, Randomized, Double-blind, Multicenter Study of TSR-042 plus Carboplatin-Paclitaxel versus Placebo plus Carboplatin-Paclitaxel in Patients with Recurrent or Primary Advanced Endometrial Cancer

To compare the progression-free survival (PFS) of treatment with dostarlimab plus carboplatin-paclitaxel to treatment with placebo plus carboplatin-paclitaxel, as assessed by the Investigator per RECIST v.1.1, in the following: [ Time Frame: Up to 5 years ] * All subjects with recurrent or...

View Details

Current Studies

Intermediate-Size Patient Population Expanded Access of NanoPac® for the Treatment of Localized Esophageal Cancer

To provide access to NanoPac to patients with localized esophageal cancer who have failed prior therapy, are not surgical candidates, or are refusing surgery at this time.

View Details

Current Studies

MK6482-011 An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti- PD-1/L

Primary Objective: -To compare MK- 6482+lenvatinib to cabozantinib with respect to PFS per Response Criteria in Solid Tumors (RECIST) 1.1 as assessed by blinded independent central review (BICR). -Hypothesis (H1): MK-6482+lenvatinib is superior to cabozantinib with respect to PFS per RECIST 1.1 by...

View Details

Current Studies

Endoscopic Mucosal Resection vs. Colon Resection: A Retrospective Efficacy and Cost Comparison Analysis in a Tertiary Community Referral Setting

Objectives 1. To compare efficacy of EMR to Laparoscopic Colon Resection (hemicolectomy) in the treatment of benign, flat colon polyps 2. To compare safety of EMR to Laparoscopic Colon Resection (hemicolectomy) in the treatment of benign, flat colon polyps 3. To compare cost...

View Details

Current Studies

Phase 2 Trial Evaluating the Safety and Tolerability of Intratumoral Injections of NanoPac® With Standard of Care Therapy in Subjects With Lung Cancer

The primary objective of this study is to evaluate the safety and tolerability of NanoPac injected into lung cancer lesions by EBUS-TBNI on multiple (up to three) occasions, each injection procedure administered 4 weeks apart. Safety and tolerability will be assessed for 24 weeks following first...

View Details

Current Studies

Penn Alliance for Therapeutic Hypothermia (PATH) Registry

The purpose of this database is to have a comprehensive look at cardiac arrest care and outcomes.

View Details

Current Studies

Endoscopic Repair of Esophageal Perforation: A Chart Review Study

It is the aim of this study to analyze the outcomes of esophageal perforation with esophageal fully covered metal stents or endoscopic suturing.

View Details

Current Studies

A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/- Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (NSCLC) (KEYN

Primary Objective: To evaluate event-free survival (EFS) by biopsy assessed by blinded central pathologist or by imaging using RECIST 1.1 assessed by blinded independent central review (BICR). To evaluate the overall survival (OS). Secondary Objective: To evaluate the rate of major pathological...

View Details

Current Studies

Phase II-III Trial of Adjuvant Radiotherapy Following Radical Prostatectomy With or Without Adjuvant Docetaxel

PRIMARY OBJECTIVES: I. To assess the benefit of docetaxel as measured by improvement in freedom from progression (phase II) and subsequently metastasis free survival (phase III) when given in combination with radiation and androgen deprivation in treatment of high risk prostate cancer post-radical...

View Details

Current Studies

Laparoscopic-Endoscopic Approach to Submucosal Mass Removal: A Chart Review Study

To assess the diagnosis, treatment and outcomes of patients with a gastrointestinal submucosal mass treated by combined laparoscopic-endoscopic removal

View Details

Current Studies

A Phase 3 Study of Pembrolizumab (MK-7339) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib Compared with Concurrent Chemoradiation Therapy Followed by Durvalumab in Participants with Unresectable,

Primary: To compare pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab plus olaparib to concurrent chemoradiation therapy followed by durvalumab with respect to progression-free survival per RECIST 1.1 as assessed by blinded independent central review. To compare...

View Details

Current Studies

Decisions About Cancer Screening in Alzheimer's Disease (DECAD)

Primary Aim: To examine the effect of a mammography screening decision aid intervention for older women with AD on markers of decision quality among caregivers. Secondary Aim: To examine the effect of a mammography screening decision aid intervention for caregivers on the utilization of mammograms...

View Details

Current Studies

HPS 4/TIMI 65 ORION 4: A double-blind randomized placebo-controlled trial assessing the effects of inclisiran on clinical outcomes among people with atherosclerotic cardiovascular disease.

The HPS-4/TIMI 65/ORION-4 study aims to provide evidence about both the efficacy and safety of inclisiran. Consistent with relevant guideline recommendations for people with vascular disease, it is intended that participants be on intensive background LDL-lowering therapy, at screening. The...

View Details

Current Studies

A Retrospective Review of the Forticore® Intervertebral Body Fusion Device in Patients with Degenerative Disc Disease

The primary objective of this retrospective data collection is to demonstrate that the Forticore intervertebral body fusion device promotes bony fusion and limits subsidence of the cervical and lumbar spine in patients with degenerative disc disease.

View Details

Current Studies

Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, the Combination of Cediranib/Olaparib and the Combination of Olaparib/Wee1 Inhibitor AZD1775 in Women With Recurrent, Persistent or Metastatic Endometrial Cancer

Primary Objective To compare the efficacy of single-agent olaparib and the combination of olaparib and cediranib (and potentially other combination arms that may be added by subsequent amendment) versus single agent cediranib as measured by progression free survival (PFS), in patients with...

View Details

Current Studies

Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer

Primary Objective: Randomized Phase II Component (Non-Inferiority): Determine whether the 12-month intracranial relapse rate following HA-PCI is non-inferior compared to the rate following PCI for patients with SCLC. Phase III Component (Efficacy): Determine whether HA-PCI reduces the likelihood of...

View Details

Current Studies

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Primary Objective a To evaluate the RECIST v1.1 overall response rate (ORR) in subsets of patients with advanced rare cancers treated with ipilimumab plus nivolumab combination immunotherapy. b To evaluate the overall response rate (ORR, per criteria in Section 10.8) in patients with gestational...

View Details

Current Studies

Randomized Phase II Study of Partial Breast Irradiation and Sequential vs. Concurrent Chemotherapy in Women with Early Stage Breast Cancer (PBI 3.0)

Primary Objective Non-inferiority of partial breast irradation (PBI) and concurrent compared to sequential chemotherapy with respect to acute grade 3-4 radiation toxicity Secondary Objectives Evaluate and compare any first tumor recurrence (local plus distant) between arms of the study. Evaluate...

View Details

Current Studies

Multi-center Prospective Evaluation of the Clinical Utility of Endoscopic Submucosal Dissection (ESD) in the Western Population

Primary An Excision of the targeted lesion in a single specimen Secondary Rate of R0 resection Time Frame 3-4 hours when all vertical and horizontal margins are negative Rate of R1 resection Time Frame 3-4 hours complete resection with no grossly visible lesion defined by...

View Details

Current Studies

Endoscopic Submucosal Dissection for Resection of T1b N0 Esophageal Cancer: A Retrospective Multicenter Trial

Central Hypothesis: Endoscopic submucosal dissection with and without adjuvant therapy (XRT, chemotherapy based on final precise pathology) allows for adequate management of T1b N0 EAC and SCC. Specific Aim #1: To assess the long-term outcomes (local and metastatic recurrence) of ESD +/- adjuvant...

View Details

Current Studies

A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)

Primary Objective To evaluate the response rate (confirmed, complete or partial) of AMG 510 in participants with KRASG12C mutated Stage IV or recurrent non-squamous non-small cell lung cancer (NSCLC). The response rates will be evaluated separately with cohorts defined as: i. Cohort 1 (co-mutation...

View Details

Current Studies

BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer

Primary Objectives 1. Examine the impact of SIGNATERATM on adjuvant treatment decisions 2. Determine the rate of patient s diagnosed with CRC recurrence while asymptomatic using SIGNATERA Secondary Objectives 1. Molecular residual disease clearance 2. Percent of patients undergoing surgery for...

View Details

Current Studies

A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian, Fallopian Tube or

Primary: Progression-free survival (PFS) To determine the efficacy by progression free survival (using investigator assessment of scans according to RECIST v1.1) of oregovomab compared to placebo when administered with background chemotherapy (paclitaxel/carboplatin) to subjects with...

View Details

Current Studies

A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Primary Objective: To evaluate whether adjuvant therapy with crizotinib will result in improved overall survival (OS) for patients with stage IB greater than or equal to 4cm, II and IIIA, ALK-positive NSCLC following surgical resection. Secondary Objectives: To evaluate and compare disease-free...

View Details

Current Studies

Parkview Health Falls Registry

Primary: * To identify risk factors in patient history among patients evaluated at the Fall Prevention Clinic. Secondary: * To compare the characteristics of adult patients who experience falls v/s those who do not. * To review findings on examination (general and neurological) and testing...

View Details

Current Studies

A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)

Primary Objective of the Master Protocol (LungMAP) The primary objective of this screening study is to test patient specimens to determine eligibility for participation in the biomarker-driven and non-matched sub-studies included within the Lung-MAP umbrella protocol. Secondary Objectives a....

View Details

Current Studies

A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum

Primary Objective To examine if letrozole monotherapy/maintenance is non-inferior to IV paclitaxel/carboplatin and maintenance letrozole with respect to PFS in women with stage II-IV primary low-grade serous carcinoma of the ovary or peritoneum after primary surgical cytoreduction. Secondary...

View Details

Current Studies

Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy

Primary Objectives: To determine if post-operative adjuvant chemo-radiation therapy (CRT) can significantly improve recurrence-free survival (RFS) when compared to radiation therapy (RT) alone in Stage I-IIA cervical cancer patients with intermediate risk factors after treatment with radical...

View Details

Current Studies

A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

Primary Objective: To evaluate whether radiation to the undissected axilla and regional lymph nodes is not inferior to axillary lymph node dissection with radiation to the regional lymph nodes but not to the dissected axilla in terms of invasive breast cancer recurrence-free interval in patients...

View Details